Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin

Phase 2

Completed

• Conditions: Advanced Gastric Cancer
• Interventions: Drug: oxaliplatin, 5-fluorouracil

• Registration Number: NCT00976768
• Lead Sponsor: Asan Medical Center

Brief Summary

The purpose of this study is:

* To observe the feasibility of biweekly oxaliplatin and infusional 5-fluorouracil (FU)/Leucovorin (LV) in patients with advanced gastric adenocarcinoma who have prior exposure to taxane, fluoropyrimidine, and cisplatin

* To determine the activity of this combination regimen.

* To evaluate the treatment-related toxicities.

Detailed Description

There is presently no chemotherapy regimen considered to be the standard of care for patients with advanced gastric cancer. However, more and more patients will receive fluoropyrimidine, platinum, and taxane combination or sequential chemotherapy. Unfortunately, about half of the patients receiving chemotherapy are unresponsive and treatment results of salvage chemotherapy are unsatisfactory. For these patients, there are currently no established palliative chemotherapy options, and there is urgent need for novel, active, and less toxic regimens for patients with advanced gastric cancer failing front-line chemotherapy.

On these bases, we will investigate the activity of biweekly oxaliplatin and 5-FU/LV in patients with advanced gastric cancer who failed prior taxane, fluoropyrimidine and cisplatin chemotherapy.

Study Timeline

• Study Start: 2004-10
• Study First Submitted: 2009-09-11
• Study First Submitted QC: 2009-09-11
• Study First Posted: 2009-09-14
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-06
• Last Update Posted: 2020-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• Pathologically proven non-resectable adenocarcinoma of stomach
• Measurable disease based on Response Criteria in Solid Tumors (RECIST)
• Prior chemotherapy with taxane, fluoropyrimidine, and cisplatinum in combination or sequentially, there is no time limit for the last chemotherapy
• Age 18 to 70 years old
• Estimated life expectancy of more than 3 months
• Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower
• Adequate bone marrow function (white blood cell counts >4,000/µL, absolute neutrophil count [ANC]>1,500/µL, hemoglobin >9.0 g/dL, and platelets>100,000/µL),
• Adequate kidney function (creatinine<1.5 mg/dL)
• Adequate liver function (bilirubin<1.5 mg/dL , transaminases levels<3 times the upper normal limit [5 times for patients with liver metastasis], and serum albumin of >2.5 mg/dL)

Read More

Exclusion Criteria

• Other tumor type than adenocarcinoma
• Presence or history of central nervous system metastasis
• Obvious or impending bowel obstruction (including obvious peritoneal carcinomatosis)
• Evidence of active gastrointestinal bleeding
• Other serious illness or medical conditions

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FOLFIRI arm	oxaliplatin, 5-fluorouracil	Patients receiving FOLFIRI

Primary Outcome Measures

Name	Time	Method
Progression-free survival	4 months

Secondary Outcome Measures

Name	Time	Method
Response rate	6 months
Toxicity profile (according to National Cancer Institute Common Terminology Criteria for Adverse Event [NCI CTC AE] version 3.0)	Each cycle of chemotherapy
Overall survival	1 year

Trial Locations

Locations (1)

Asan medical center; 🇰🇷 Seoul, Korea, Republic of